Horstkotte D - Search Results

1

Lipid apheresis: oxidative stress, rheology, and vasodilatation.

Mellwig KP, Pulawski E, Horstkotte D, van Buuren F. Mellwig KP, et al. Among authors: horstkotte d. Clin Res Cardiol Suppl. 2012 Jun;7(Suppl 1):45-9. doi: 10.1007/s11789-012-0043-9. Clin Res Cardiol Suppl. 2012. PMID: 22528131 Free PMC article. Clinical Trial.

2

Improved coronary vasodilatatory capacity by H.E.L.P. apheresis: comparing initial and chronic treatment.

Mellwig KP, van Buuren F, Schmidt HK, Wielepp P, Burchert W, Horstkotte D. Mellwig KP, et al. Among authors: horstkotte d. Ther Apher Dial. 2006 Dec;10(6):510-7. doi: 10.1111/j.1744-9987.2006.00441.x. Ther Apher Dial. 2006. PMID: 17199883 Clinical Trial.

3

HELP apheresis in hypercholesterolemia and cardiovascular disease: efficacy and adverse events after 8,500 procedures.

van Buuren F, Kreickmann S, Horstkotte D, Kottmann T, Mellwig KP. van Buuren F, et al. Among authors: horstkotte d. Clin Res Cardiol Suppl. 2012 Jun;7(Suppl 1):24-30. doi: 10.1007/s11789-012-0048-4. Clin Res Cardiol Suppl. 2012. PMID: 22528135 Free PMC article.

4

Lipoprotein (a) and coronary heart disease - is there an efficient secondary prevention?

Mellwig KP, Horstkotte D, van Buuren F. Mellwig KP, et al. Among authors: horstkotte d. Clin Res Cardiol Suppl. 2017 Mar;12(Suppl 1):18-21. doi: 10.1007/s11789-017-0088-x. Clin Res Cardiol Suppl. 2017. PMID: 28233270 Free PMC article.

5

[Heparin-induced extracorporeal LDL precipitation (H.E.L.P.)].

Horstkotte D, Mellwig KP. Horstkotte D, et al. Z Kardiol. 2003;92(Suppl 3):III1-5. doi: 10.1007/s00392-003-1304-x. Z Kardiol. 2003. PMID: 14663596 Review. German.

6

[Myocardial perfusion under H.E.L.P. -apheresis. Objectification by PET].

Mellwig KP, Baller D, Schmidt HK, V Buuren F, Wielepp JP, Burchert W, Horstkotte D. Mellwig KP, et al. Among authors: horstkotte d. Z Kardiol. 2003;92(Suppl 3):III30-7. doi: 10.1007/s00392-003-1303-y. Z Kardiol. 2003. PMID: 14663599 Clinical Trial. German.

7

[H.E.L.P. apheresis and oxidative stress].

Pulawski E, Mellwig KP, Horstkotte D. Pulawski E, et al. Among authors: horstkotte d. Z Kardiol. 2003;92(Suppl 3):III38-41. doi: 10.1007/s00392-003-1306-8. Z Kardiol. 2003. PMID: 14663600 Clinical Trial. German.

8

[Lipoprotein(a): influence on cardiovascular manifestation].

Mellwig KP, Schatton C, Biermann B, Kottmann T, Horstkotte D, van Buuren F. Mellwig KP, et al. Among authors: horstkotte d. Clin Res Cardiol Suppl. 2015 Apr;10:33-8. doi: 10.1007/s11789-015-0072-2. Clin Res Cardiol Suppl. 2015. PMID: 25666917 German.

9

Beneficial effects of atorvastatin on myocardial regions with initially low vasodilatory capacity at various stages of coronary artery disease.

Wielepp P, Baller D, Gleichmann U, Pulawski E, Horstkotte D, Burchert W. Wielepp P, et al. Among authors: horstkotte d. Eur J Nucl Med Mol Imaging. 2005 Dec;32(12):1371-7. doi: 10.1007/s00259-005-1828-6. Epub 2005 Aug 31. Eur J Nucl Med Mol Imaging. 2005. PMID: 16133398 Clinical Trial.

10

[Extracardiac manifestation of elevated lipoprotein(a) levels--cumulative incidence of peripheral arterial disease and stenosis of the carotid artery].

van Buuren F, Sommer JA, Kottmann T, Horstkotte D, Mellwig KP. van Buuren F, et al. Among authors: horstkotte d. Clin Res Cardiol Suppl. 2015 Apr;10:39-45. doi: 10.1007/s11789-015-0069-x. Clin Res Cardiol Suppl. 2015. PMID: 25666916 German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

475 results

Search Page